Laboratory Medicine ›› 2021, Vol. 36 ›› Issue (1): 48-52.DOI: 10.3969/j.issn.1673-8640.2021.01.010
Previous Articles Next Articles
LIAO Shengjun, XU Xianqun, ZHAO Jin, LI Siwei, QIU Xueping, CHEN Liangjun, LI Yirong()
Received:
2020-03-25
Online:
2021-01-30
Published:
2021-02-05
CLC Number:
LIAO Shengjun, XU Xianqun, ZHAO Jin, LI Siwei, QIU Xueping, CHEN Liangjun, LI Yirong. Correlation between some laboratory indexes and severity of COVID-19 in 144 patients[J]. Laboratory Medicine, 2021, 36(1): 48-52.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2021.01.010
组别 | WBC计数/(×109/L) | Hb/(g/L) | PLT计数/(×109/L) | NEUT#/(×109/L) | LYMPH#/(×109/L) |
---|---|---|---|---|---|
普通组 | 5.22(4.02,6.38) | 129.1(121.0,138.8) | 214.36±56.86 | 3.00(2.33,3.49) | 1.61(1.30,1.97) |
重症组 | 7.26(6.06,9.82) | 114.0(74.0,128.0) | 214.23±88.69 | 6.91(5.61,8.77) | 0.55(0.27,0.85) |
参考区间 | 3.5~9.5 | 130~175 | 125~350 | 1.8~6.3 | 1.1~3.2 |
P值 | 0.000 | 0.002 | 0.950 | 0.000 | 0.000 |
组别 | NLR | NEUT%/% | LYMPH%/% | MCV/fL | RDW/% |
普通组 | 1.85(1.31,2.46) | 53.31(43.91,67.29) | 33.25(26.37,45.93) | 94.34(86.20,95.76) | 13.55(13.00,14.30) |
重症组 | 12.22(6.93,28.81) | 81.90(76.40,92.15) | 8.50(3.85,13.65) | 95.60(91.50,98.20) | 13.30(13.00,13.70) |
参考区间 | 0.9~3.0 | 40~75 | 20~50 | 82~100 | 10.1~16.0 |
P值 | 0.000 | 0.000 | 0.000 | 0.294 | 0.596 |
组别 | WBC计数/(×109/L) | Hb/(g/L) | PLT计数/(×109/L) | NEUT#/(×109/L) | LYMPH#/(×109/L) |
---|---|---|---|---|---|
普通组 | 5.22(4.02,6.38) | 129.1(121.0,138.8) | 214.36±56.86 | 3.00(2.33,3.49) | 1.61(1.30,1.97) |
重症组 | 7.26(6.06,9.82) | 114.0(74.0,128.0) | 214.23±88.69 | 6.91(5.61,8.77) | 0.55(0.27,0.85) |
参考区间 | 3.5~9.5 | 130~175 | 125~350 | 1.8~6.3 | 1.1~3.2 |
P值 | 0.000 | 0.002 | 0.950 | 0.000 | 0.000 |
组别 | NLR | NEUT%/% | LYMPH%/% | MCV/fL | RDW/% |
普通组 | 1.85(1.31,2.46) | 53.31(43.91,67.29) | 33.25(26.37,45.93) | 94.34(86.20,95.76) | 13.55(13.00,14.30) |
重症组 | 12.22(6.93,28.81) | 81.90(76.40,92.15) | 8.50(3.85,13.65) | 95.60(91.50,98.20) | 13.30(13.00,13.70) |
参考区间 | 0.9~3.0 | 40~75 | 20~50 | 82~100 | 10.1~16.0 |
P值 | 0.000 | 0.000 | 0.000 | 0.294 | 0.596 |
组别 | TNF-a/(pg/mL) | IFN-γ/(pg/mL) | IL-2/(pg/mL) | IL-4/(pg/mL) | IL-6/(pg/mL) | |||
---|---|---|---|---|---|---|---|---|
普通组 | 0.1(0.1,0.1) | 0.26(0.11,1.33) | 0.83(0.13,1.73) | 0.37(0.10,1.53) | 0.62(0.10,3.49) | |||
重症组 | 0.1(0.1,0.1) | 0.71(0.11,2.03) | 1.10(0.18,1.90) | 0.37(0.10,1.34) | 5.45(0.30,12.07) | |||
参考区间 | 0.1~23.0 | 0.1~18.0 | 0.1~4.1 | 0.1~3.2 | 0.1~2.9 | |||
P值 | 0.758 | 0.302 | 0.783 | 0.963 | 0.002 | |||
组别 | IL-10/(pg/mL) | CRP/(mg/mL) | SAA/(mg/L) | DD/(ng/mL) | ||||
普通组 | 1.25(0.75,4.06) | 2.1(1.2,4.7) | 7.13(5.27,10.39) | 167.5(107.0,253.5) | ||||
重症组 | 3.22(1.46,6.58) | 22.9(6.7,56.5) | 160.20(49.40,193.90) | 1 788.5(519.0,3 500.0) | ||||
参考区间 | 0.1~5.0 | 0~10.0 | 0~10.0 | 0~500.0 | ||||
P值 | 0.001 | 0.000 | 0.000 | 0.000 |
组别 | TNF-a/(pg/mL) | IFN-γ/(pg/mL) | IL-2/(pg/mL) | IL-4/(pg/mL) | IL-6/(pg/mL) | |||
---|---|---|---|---|---|---|---|---|
普通组 | 0.1(0.1,0.1) | 0.26(0.11,1.33) | 0.83(0.13,1.73) | 0.37(0.10,1.53) | 0.62(0.10,3.49) | |||
重症组 | 0.1(0.1,0.1) | 0.71(0.11,2.03) | 1.10(0.18,1.90) | 0.37(0.10,1.34) | 5.45(0.30,12.07) | |||
参考区间 | 0.1~23.0 | 0.1~18.0 | 0.1~4.1 | 0.1~3.2 | 0.1~2.9 | |||
P值 | 0.758 | 0.302 | 0.783 | 0.963 | 0.002 | |||
组别 | IL-10/(pg/mL) | CRP/(mg/mL) | SAA/(mg/L) | DD/(ng/mL) | ||||
普通组 | 1.25(0.75,4.06) | 2.1(1.2,4.7) | 7.13(5.27,10.39) | 167.5(107.0,253.5) | ||||
重症组 | 3.22(1.46,6.58) | 22.9(6.7,56.5) | 160.20(49.40,193.90) | 1 788.5(519.0,3 500.0) | ||||
参考区间 | 0.1~5.0 | 0~10.0 | 0~10.0 | 0~500.0 | ||||
P值 | 0.001 | 0.000 | 0.000 | 0.000 |
组别 | CD3+百分比/% | CD3+CD4+百分比/% | CD3+CD8+百分比/% | Th①/Ts② | CD19+百分比/% | NK③百分比/% | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
普通组 | 69.48 (63.52,75.26) | 41.04 (35.29,46.72) | 26.00 (20.43,30.68) | 1.63 (1.27,2.21) | 12.82 (8.72,15.16) | 16.48 (10.88,23.34) | ||||||
重症组 | 72.29 (62.47,77.22) | 42.95 (30.37,51.09) | 24.88 (17.90,32.18) | 1.78 (1.00,3.02) | 13.94 (7.40,20.90) | 9.74 (4.43,15.99) | ||||||
参考区间 | 38.56~70.06 | 14.21~36.99 | 13.24~38.53 | 0.96~2.05 | 10.86~28.03 | 7.92~33.99 | ||||||
P值 | 0.465 | 0.435 | 0.949 | 0.807 | 0.359 | 0.000 | ||||||
组别 | CD3+/µL | CD3+CD4+/µL | CD3+CD8+/µL | CD19+/µL | NK/µL | |||||||
普通组 | 1 137(917,1 502) | 679(552,924) | 422(315,514) | 216(124,286) | 244(167,430) | |||||||
重症组 | 430(271,733) | 258(163,490) | 162(97,261) | 96(56,140) | 57(21,134) | |||||||
参考区间 | 805~4 459 | 345~2 350 | 345~2 350 | 240~1 317 | 210~1 514 | |||||||
P值 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 |
组别 | CD3+百分比/% | CD3+CD4+百分比/% | CD3+CD8+百分比/% | Th①/Ts② | CD19+百分比/% | NK③百分比/% | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
普通组 | 69.48 (63.52,75.26) | 41.04 (35.29,46.72) | 26.00 (20.43,30.68) | 1.63 (1.27,2.21) | 12.82 (8.72,15.16) | 16.48 (10.88,23.34) | ||||||
重症组 | 72.29 (62.47,77.22) | 42.95 (30.37,51.09) | 24.88 (17.90,32.18) | 1.78 (1.00,3.02) | 13.94 (7.40,20.90) | 9.74 (4.43,15.99) | ||||||
参考区间 | 38.56~70.06 | 14.21~36.99 | 13.24~38.53 | 0.96~2.05 | 10.86~28.03 | 7.92~33.99 | ||||||
P值 | 0.465 | 0.435 | 0.949 | 0.807 | 0.359 | 0.000 | ||||||
组别 | CD3+/µL | CD3+CD4+/µL | CD3+CD8+/µL | CD19+/µL | NK/µL | |||||||
普通组 | 1 137(917,1 502) | 679(552,924) | 422(315,514) | 216(124,286) | 244(167,430) | |||||||
重症组 | 430(271,733) | 258(163,490) | 162(97,261) | 96(56,140) | 57(21,134) | |||||||
参考区间 | 805~4 459 | 345~2 350 | 345~2 350 | 240~1 317 | 210~1 514 | |||||||
P值 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 |
项目 | β值 | 标准误 | Wald检验 | P值 | 优势比 |
---|---|---|---|---|---|
WBC计数 | 0.570 | 0.115 | 24.675 | 0.000 | 1.767 |
Hb | -0.032 | 0.010 | 13.466 | 0.002 | 0.969 |
NEUT% | 0.226 | 0.038 | 34.822 | 0.000 | 1.254 |
LYMPH% | -0.293 | 0.049 | 36.025 | 0.000 | 0.074 |
NLR | 1.451 | 0.309 | 22.030 | 0.000 | 4.269 |
CRP | 0.152 | 0.041 | 13.626 | 0.000 | 1.165 |
SAA | 0.093 | 0.025 | 13.466 | 0.000 | 1.098 |
DD | 0.001 | 0.000 | 23.813 | 0.000 | 1.001 |
IL-6 | 0.082 | 0.040 | 4.254 | 0.039 | 1.085 |
IL-10 | 0.036 | 0.019 | 3.742 | 0.053 | 1.037 |
项目 | β值 | 标准误 | Wald检验 | P值 | 优势比 |
---|---|---|---|---|---|
WBC计数 | 0.570 | 0.115 | 24.675 | 0.000 | 1.767 |
Hb | -0.032 | 0.010 | 13.466 | 0.002 | 0.969 |
NEUT% | 0.226 | 0.038 | 34.822 | 0.000 | 1.254 |
LYMPH% | -0.293 | 0.049 | 36.025 | 0.000 | 0.074 |
NLR | 1.451 | 0.309 | 22.030 | 0.000 | 4.269 |
CRP | 0.152 | 0.041 | 13.626 | 0.000 | 1.165 |
SAA | 0.093 | 0.025 | 13.466 | 0.000 | 1.098 |
DD | 0.001 | 0.000 | 23.813 | 0.000 | 1.001 |
IL-6 | 0.082 | 0.040 | 4.254 | 0.039 | 1.085 |
IL-10 | 0.036 | 0.019 | 3.742 | 0.053 | 1.037 |
[1] | 国家卫生健康委办公厅. 新型冠状病毒感染的肺炎诊疗方案(试行第五版)[EB/OL].(2020-02-05)[2020-03-20]. . |
[2] | HUANG C,WANG Y,LI X,et al.Clinical features of patients infected with 2019 novel coronavirus in Wuhan,China[J]. Lancet,2020,395(10223):497-506. |
[3] | 国家卫生健康委办公厅. 新型冠状病毒肺炎诊疗方案(试行第七版)[EB/OL].(2020-03-03)[2020-03-20]. . |
[4] | ZHAO Y,ZHAO Z,WANG Y,et al.Single-cell RNA expression profiling of ACE2,the receptor of SARS-CoV-2[J]. Am J Respir Crit Care Med,2020,202(5):756-759. |
[5] | LIU Y,YANG Y,ZHANG C,et al.Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury[J]. Sci China Life Sci,2020,63(3):364-374. |
[6] | LIU J,LIU Y,XIANG P,et al.Neutrophil-to-lymphocyte ratio predicts critical illness patients with 2019 novel coronavirus disease in the early stage[J]. J Transl Med,2020,18(1):206. |
[7] | 颜宇飞,金一鸣,刘明利,等. NLR在SARS-CoV-2感染中的临床意义[J]. 检验医学,35(7):637-639. |
[8] | QU J,LÜ X,LIU Y,et al.Evaluation of procalcitonin,C-reactive protein,interleukin-6 & serum amyloid A as diagnostic biomarkers of bacterial infection in febrile patients[J]. Indian J Med Res,2015,141(3):315-321. |
[9] | WANG D,HU B,HU C,et al.Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan,China[J]. JAMA,2020,323(11):1061-1069. |
[10] | 中华医学会呼吸病学分会肺栓塞与肺血管病学组,中国医师协会呼吸医师分会肺栓塞与肺血管病工作委员会,全国肺栓塞与肺血管病防治协作组,等. 新型冠状病毒肺炎相关静脉血栓栓塞症防治建议(试行)[J]. 中华医学杂志,2020,100(11):808-813. |
[11] | CHEN N,ZHOU M,DONG X,et al.Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan,China:a descriptive study[J]. Lancet,2020,395(10223):507-513. |
[12] | FANG Y,ZHANG H,XU Y,et al.CT manifestations of two cases of 2019 novel coronavirus(2019-nCoV) pneumonia[J]. Radiology,2020,295(1):208-209. |
[13] | XU Z,SHI L,WANG Y,et al.Pathological findings of COVID-19 associated with acute respiratory distress syndrome[J]. Lancet Respir Med,2020,8(4):420-422. |
[1] | XIANG Jin, LIU Aiping, HU Yao, WU Zhiyuan, CAO Guojun, GUAN Ming. ANA profiles in COVID-19 patients and influence of serum heat-inactivation on ANA determination [J]. Laboratory Medicine, 2023, 38(12): 1141-1146. |
[2] | YUE Caidie, LI Junyan, DING Aijun, XIE Li, ZENG Weikun. Research progress of rapid determination methods for SARS-CoV-2 antigen [J]. Laboratory Medicine, 2023, 38(1): 87-93. |
[3] | SUN Jiaqi, JIN Weifeng, LI Ping, CHEN Shuzi, LIN Ping, LI Dan, CHEN Qing, WANG Mengxia, ZHU Yuxin. Influence of heat inactivation of blood samples at 56 ℃ for 30 min on psychiatric drug concentration monitoring [J]. Laboratory Medicine, 2022, 37(12): 1174-1177. |
[4] | HUANG Fei, ZHANG Chunyan, GUO Wei, PAN Baishen, WANG Beili. Status and problems of SARS-CoV-2 nucleic acid detection [J]. Laboratory Medicine, 2021, 36(5): 554-559. |
[5] | HU Senan, TAN Junfeng, PENG Chang, AI Honghong, LI Dan. Role of blood glucose variability in the prognosis of severe corona virus disease 2019 patients [J]. Laboratory Medicine, 2021, 36(4): 400-403. |
[6] | WANG Bin. Correlation between neutrophil-to-lymphocyte ratio and short-term poor prognosis in patients with corona virus disease 2019 [J]. Laboratory Medicine, 2021, 36(3): 275-280. |
[7] | ZHU Chuanxin, ZHOU Yuping, HE Yan, ZHOU Qin. Diagnostic role of NLR,CRP,PCT,DD and NT-proBNP in severe corona virus disease 2019 [J]. Laboratory Medicine, 2021, 36(2): 190-193. |
[8] | LI Shichao, SHEN Liang, WANG Chunhua, TONG Yanfei, ZHANG Ji. Diagnostic value of SARS-CoV-2 antibody to COVID-19:a meta-analysis [J]. Laboratory Medicine, 2021, 36(1): 39-43. |
[9] | FAN Jian, GUO Ying, QI Weiqiang, HAO Menglu, ZHANG Tengfei, ZHU Zhaoqin. Analysis on the absolute value of lymphocyte in COVID-19 patients before and after recovery in Shanghai [J]. Laboratory Medicine, 2021, 36(1): 44-47. |
[10] | ZHU Chuanxin, ZHOU Yuping, ZHOU Qin, ZHOU Guifeng. Early diagnosis value of NLR,PCT and CRP combined determination for COVID-19 [J]. Laboratory Medicine, 2021, 36(1): 53-56. |
[11] | WANG Xiaowu, GAO Yong, WU Dong. Prediction of severe corona virus disease 2019 by coagulation indicators [J]. Laboratory Medicine, 2021, 36(1): 57-59. |
[12] | ZHANG Tengfei, QI Weiqiang, LING Yun, ZAI Shubei, WANG Yan, FAN Jian, ZHANG Bei, ZHU Zhaoqin. Correlation between urinary protein and disease progression in COVID-19 patients [J]. Laboratory Medicine, 2020, 35(9): 872-874. |
[13] | HUANG Shaokun, ZHONG Qingyang, ZHU Haipeng, LUO Rundi, ZHANG Jianming. Roles of dynamic monitoring of SARS-CoV-2 antibodies in the diagnosis of COVID-19 [J]. Laboratory Medicine, 2020, 35(9): 895-899. |
[14] | ZHAO Minghai, LI Xin, WEI Dong, LUO Min, ZHANG Yajie, YANG Yiqi, ZHENG Lei. Influence of dry heat inactive treatment for the determination of inflammatory indicators related with corona virus disease 2019 [J]. Laboratory Medicine, 2020, 35(9): 924-927. |
[15] | CHANG Zhongyong, LIAO Guolin, WANG Qiang, YANG Weibin. Analysis of mixed infection with common respiratory tract pathogens in patients with corona virus disease 2019 [J]. Laboratory Medicine, 2020, 35(8): 775-777. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||